Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Multimodal Pain Plan to Cut Opioids After Hip Replacement

Official title: Multimodal Analgesic Regimen for Total Hip Arthroplasty: An Initiative to Minimize Postoperative Opioid Use

Run by Henry Ford Health System · NCT07672808 · Data updated 2026-11-12

This study tests whether a multimodal pain regimen with a printed opioid prescription (instead of pharmacy-direct dispensing) can control pain after hip replacement while reducing opioid use.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment100 (estimated)
SponsorHenry Ford Health System
Academic / other
Locations1 site (Detroit, Michigan)
StatusRecruiting
StartedJuly 20, 2026
Main results expectedDecember 1, 2026
Study endsMay 30, 2027
Registry record updatedOctober 7, 2026
Trial IDNCT07672808 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18 or older undergoing total hip arthroplasty by a single fellowship-trained orthopedic surgeon who can adhere to the study procedures.

Probably not a fit

Patients who require high levels of opioid analgesia or have contraindications to multimodal regimens may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults undergoing total hip arthroplasty are randomized to receive either the standard pain regimen or a variant where the opioid prescription is provided as a printed copy only, allowing the patient to decide whether to fill it. Both groups use a multimodal set of pain medications, and all participants track pain and medication use for 21 days, with follow-up on function and well-being over three months. The goal is to determine if delaying or limiting direct opioid dispensing can lower opioid consumption without compromising pain control. Outcomes include total opioid use, pain scores, recovery metrics, and patient-reported quality of life. The study is conducted at Henry Ford Hospital in Detroit under the leadership of Henry Ford Health System.

Why it matters

Potential benefit: If successful, patients may experience less opioid exposure after hip replacement without sacrificing pain relief or recovery.

How similar studies have gone: Previous research supports multimodal analgesia for reducing opioid use, but the specific printed-prescription approach is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adult patients age 18 and older
* Patients who have undergone total hip arthroplasty by a single, fellowship trained Orthopaedic Surgeon.

Exclusion Criteria:

* Patients with incomplete data in medical records
* Chronic opioid use in the last 3 months
* Ipsilateral joint surgery in the last year
* Cannot tolerate oral medications
* Swallowing difficulties
* Intolerance to Tylenol, Celebrex, Robaxin, Neurontin, or Tramadol
* History of Alcohol abuse
* History of Drug abuse
* History of Renal impairment
* History of Peptic ulcer disease
* History of GI bleeding
* Illicit narcotic usage in past 6 months
* Chronic liver disease
* Chronic pain syndrome

Where it's running

  • Henry Ford Hospital
    Detroit, Michigan, United States
    Recruiting

Study contacts

  • Principal investigator: Michael Charters, MD — Henry Ford Health System
  • Study coordinator: Antonio M Pellerito, BA
  • Email: ampeller@umich.edu
  • Phone: 586-859-3258

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.